[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SleepRes Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,61,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100650763","kpap-vs-airsense-11-with-epr-100650763",false,"NCT07751562","KPAP vs AirSense 11 With EPR","A Randomized Crossover Study of Automatic Positive Airway Pressure (APAP) Treatment Efficacy: Kairos APAP (With KPAP) Versus ResMed AirSense APAP With EPR","Inclusion criteria:\n\n* BMI above 18 kg\u002Fm2, inclusive\n* Diagnosis of OSA meeting all the following criteria: AHI4 \\> 10 on a previous PSG or HST (within the past 2 years), central apneas \\\u003C 25% of events, PLM arousal index \\\u003C 15 if recorded\n* Current treatment with PAP of any nightly duration.\n* Subject is fluent in English and subject understands the study protocol and is willing and able to comply with study requirements and sign informed consent.\n* Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the study-related procedures.\n\nExclusion Criteria\n\n* A female of child-bearing potential that is pregnant or intends to become pregnant.\n* Any unstable or severe medical condition of any organ system including congestive heart failure, COPD, renal failure, neuromuscular disease, etc., or at the discretion of the site Principal Investigator (PI).\n* Taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, anticonvulsants, etc.\n* The presence of any other sleep disorder (insomnia, periodic limb movement disorder, etc).\n* The presence of a psychiatric disorder, including attempted suicide within 1 year prior to screening, or current suicidal ideation.\n* A serious illness or infection in the past 30 days.\n* Prior\u002FConcomitant Therapy including: chronic nocturnal oxygen therapy, mandibular advancement device, active hypoglossal nerve stimulation implant.\n* Excessive alcohol consumption (\\>21 drinks\u002Fweek).\n* The use of any illegal drug(s).","ALL","21 Years","80 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The KPAP vs AirSense 11 with EPR study is a randomized, crossover study in which treatment efficacy will be compared between SleepRes APAP + KPAP and ResMed APAP + EPR. Participants will be chosen from those with a formal OSA diagnosis (following an in-lab polysomnogram, a split-night study or a home sleep apnea test) within the past 2 years and on PAP therapy.\n\nUpon signing an informed consent, participants will be randomized to the order of study and which device will be used first: APAP + KPAP (delivered by a SleepRes device) or APAP + EPR (delivered by a ResMed device). Participants will be blinded to the sequence order. They will then be invited to the laboratory for two overnight sleep studies, one on each treatment device, in the order determined by the randomization. Prior to each overnight, they will have to observe withdrawal of their home PAP treatment for 3 nights. The KPAP drop will be set to the maximum level (i.e., 5 cmH2O), while EPR will be set on 3. APAP from both manufacturers will be set on a 5-20 cmH2O pressure range. The next morning of each sleep study, participants will be administered visual analog scale (VAS) questionnaires to examine subjective sleep quality (1=best sleep quality; 10=worst sleep quality) and, after all studies are completed, a device subjective preference (1=APAP+KPAP was extremely better than APAP+EPR; 10=the opposite).\n\nThe study will be single blinded with both the participants (the device will be concealed in the laboratory so that participants will not be able to understand what treatment they are on) and the registered technician scoring the polysomnograms (by an independent scoring partner, Sleep Strategies) blinded to treatment allocation.",[27],"Sleep Apnea, Obstructive","NOT_YET_RECRUITING","2026-08-03",{"date":31,"type":32},"2026-08-07","ACTUAL",{"date":34,"type":21},"2026-09-01",{"date":36,"type":21},"2027-02-28",{"name":38,"class":39},"SleepRes Inc.","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100633733","kpap-vs-epr-for-efficacy-100633733","NCT07530523","KPAP vs EPR for Efficacy","A Randomized Crossover Study of Continuous Positive Airway Pressure (CPAP) Treatment Efficacy: Kairos PAP (KPAP) Versus Expiratory Pressure Relief (EPR)","Inclusion Criteria:\n\n* BMI above 18 kg\u002Fm2, inclusive\n* Recent formal diagnosis of OSA meeting all the following criteria: AHI \\> 10, Central apneas \\\u003C 25% of events, PLM arousal index \\\u003C 15, no prior\u002Fconcomitant OSA therapy\n* Subject is fluent in English and subject understands the study protocol and is willing and able to comply with study requirements and sign informed consent.\n* Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the study-related procedures.\n\nExclusion Criteria:\n\n* A female of child-bearing potential that is pregnant or intends to become pregnant.\n* Any unstable or severe medical condition of any organ system including congestive heart failure, COPD, renal failure, neuromuscular disease, etc., or at the discretion of the site Principal Investigator (PI).\n* Taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, anticonvulsants, etc.\n* The presence of any other sleep disorder (insomnia, periodic limb movement disorder, etc.).\n* The presence of a psychiatric disorder, including attempted suicide within 1 year prior to screening, or current suicidal ideation.\n* A serious illness or infection in the past 30 days.\n* Excessive alcohol consumption (\\>21 drinks\u002Fweek).\n* The use of any illegal drug(s).\n* Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.\n* Chronic nocturnal oxygen therapy.\n* Active hypoglossal nerve stimulation implant.","20 Years",{"count":49,"type":21},24,[24],"The KPAP EPR is a randomized, crossover study in which treatment efficacy will be compared between SleepRes CPAP + KPAP and ResMed CPAP + EPR. Participants will be chosen from those with a recent OSA diagnosis (following an in-lab polysomnogram, a split-night study or a home sleep apnea test) and with no previous use of OS therapy (PAP-naïve).\n\nUpon signing an informed consent, participants will be scheduled to come to the sleep laboratory for a manual titration on CPAP. Once the therapeutic pressure is determined, participants will be randomized to start either CPAP + KPAP (delivered by a SleepRes device) or CPAP + EPR (delivered by a ResMed device). Participants will be blinded to the sequence order. They will then be invited to the laboratory for two overnight sleep studies, one on each treatment device, in the order determined by the randomization, with a minimum washout of 1 week and a maximum of 3 weeks. Both studies will use the therapeutic pressure determined during manual titration. The KPAP drop will be set to the maximum level (i.e., 5 cmH2O), while EPR will be set on 3. The next morning of each sleep study, participants will be administered visual analog scale (VAS) questionnaires to examine subjective sleep quality (1=best sleep quality; 10=worst sleep quality) and, after all studies are completed a device subjective preference (1=CPAP+KPAP was extremely better than CPAP+EPR; 10=the opposite).\n\nThe study will be single blinded with both the participants (the device will be concealed in the laboratory so that participants will not be able to understand what treatment they are on) and the registered technician scoring the polysomnographies blinded to treatment allocation.",[53],"Obstructive Sleep Apnea",{"date":55,"type":32},"2026-08-04",{"date":57,"type":21},"2027-03-01",{"date":59,"type":21},"2027-12-31",{"name":38,"class":39},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":18,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100547835","kpap-adherence-crossover-study-100547835","NCT06413134","KPAP Adherence Crossover Study","A Prospective, Randomized, Crossover Study of Therapy Adherence With Kairos Positive Airway Pressure (KPAP) Compared to Automatic Adjusting Positive Airway Pressure (APAP) for the Treatment of Obstructive Sleep Apnea (OSA)","Inclusion Criteria:\n\n1. AHI \\> 10 on a previous PSG or HST (hypopneas requiring 4% desaturation).\n2. Central apneas \\\u003C 25% of events\n3. PLM (Periodic Limb Movements) arousal index \\\u003C 15\n\nExclusion Criteria:\n\n1. A female of child-bearing potential that is pregnant or intends to become pregnant.\n2. Any unstable or severe medical condition of any organ system including congestive heart failure, COPD, renal failure, neuromuscular disease, etc., or at the discretion of the site Principal Investigator (PI).\n3. Taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, anticonvulsants, etc.\n4. The presence of any other sleep disorder (insomnia, periodic limb movement disorder, etc).\n5. Prior therapy or treatment for OSA.\n6. Chronic oxygen therapy.\n7. Excessive alcohol consumption (\\>14 drinks\u002Fweek).\n8. The use of any illegal drug(s).\n9. Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.",{"count":20,"type":21},[24],"A device able to provide less positive airway pressure (PAP) for the entire duration of inspiration and roughly half the duration of expiration, designated KPAP, is being developed by SleepRes for the treatment of obstructive sleep apnea (OSA). In prior studies, the administration of higher inspiratory than expiratory PAP did not substantially increase treatment efficacy or adherence to continuous PAP (CPAP), which remains low. In our recent investigation, we demonstrated that the addition of a resistor to the CPAP circuit to reduce inspiratory PAP increased subjective comfort. In another study, we showed that KPAP improved subjective comfort during wakefulness vs. fixed CPAP, while maintaining treatment efficacy. The present study, KPAP Adherence 1, is a randomized, crossover study designed to examine whether KPAP can improve adherence over APAP as an at home treatment for OSA.",[53],"2026-05-04",{"date":74,"type":32},"2026-05-06",{"date":76,"type":21},"2026-07-01",{"date":78,"type":21},"2026-12-31",{"name":38,"class":39},1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":18,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":4},"100633732","kpap-vs-epr-for-comfort-100633732","NCT07530510","KPAP vs EPR for Comfort","A Randomized Crossover Study of Subjective Comfort With At-Home Auto-Titrating Positive Airway Pressure (APAP): Kairos PAP (KPAP) Versus Expiratory Pressure Relief (EPR)","Inclusion Criteria:\n\n* BMI above 18 kg\u002Fm2, inclusive\n* Recent formal diagnosis of OSA meeting all the following criteria: AHI \\> 10, Central apneas \\\u003C 25% of events, PLM arousal index \\\u003C 15, no prior\u002Fconcomitant OSA therapy\n* Subject is fluent in English and subject understands the study protocol and is willing and able to comply with study requirements and sign informed consent.\n* Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the study-related procedures.\n\nExclusion Criteria:\n\n* A female of child-bearing potential that is pregnant or intends to become pregnant.\n* Any unstable or severe medical condition of any organ system including congestive heart failure, COPD, renal failure, neuromuscular disease, etc., or at the discretion of the site Principal Investigator (PI).\n* Taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, anticonvulsants, etc.\n* The presence of any other sleep disorder (insomnia, periodic limb movement disorder, etc.).\n* The presence of a psychiatric disorder, including attempted suicide within 1 year prior to screening, or current suicidal ideation.\n* A serious illness or infection in the past 30 days.\n* Excessive alcohol consumption (\\>21 drinks\u002Fweek).\n* The use of any illegal drug(s).\n* Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.",{"count":49,"type":21},[24],"The KPAP EPR Home is a randomized, crossover study in which subjective comfort will be compared between SleepRes APAP + KPAP and ResMed APAP + EPR. Participants will be individuals with newly diagnosed OSA who have not previously tried any PAP treatment (PAP-naïve).\n\nUpon signing an informed consent, participants will be randomized to receiving either APAP + KPAP (delivered by a SleepRes device) or APAP + EPR (delivered by a ResMed device) for home use. Participants will be asked to use the devices (in the order of randomization) for 4 days each, with 3 days of washout in between. Participants will be blinded to the sequence order, even though they will receive machines that are not identical at each treatment. The KPAP drop will be set to the maximum level (i.e., 5 cmH2O), while EPR will be set on 3. APAP will be set on the full pressure range (i.e., 5-20 cmH2O). After each period, each individual will be asked to rate their device preference according to a 10-point visual analog (VAS) scale (i.e., 1=extremely uncomfortable treatment; 10=extremely comfortable treatment). After usage, the devices will be returned to the office and device data will be downloaded.",[53],"2026-04-08",{"date":94,"type":32},"2026-04-15",{"date":96,"type":21},"2026-06-01",{"date":78,"type":21},{"name":38,"class":39},""]